Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin

Journal of Hepatology

Volumn 56, Issue 6, 2012, Pages 1276-1282

  Marcellin, Patrick ^a   Reau, Nancy ^b   Ferenci, Peter ^c   Hadziyannis, Stephanos ^d   Messinger, Diethelm ^e   Tatsch, Fernando ^f   Jensen, Donald ^b  

^a BEAUJON HOSPITAL   (France)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d HENRY DUNANT HOSPITAL   (Greece)

^e IST GmbH   (Germany)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Hepatitis C; Peginterferon; Peginterferon alfa 2a; Sustained virological response; Week 4

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAPID VIROLOGICAL RESPONSE; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROBABILITY; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL;

EID: 84861183101     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.12.026     Document Type: Article

References (30)

1. J.L. Dienstag, and J.G. McHutchison American Gastroenterological Association technical review on the management of hepatitis C Gastroenterology 130 2006 231 264 (Pubitemid 43049856)
2. S. Zeuzem, J.M. Pawlotsky, E. Von Lukasiewicz, M. Wagner, I. Goulis, and Y. Lurie International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C J Hepatol 43 2005 250 257 (Pubitemid 40956877)
3. P. Marcellin, and J.P. Benhamou Treatment of chronic viral hepatitis Baillieres Clin Gastroenterol 8 1994 233 253 (Pubitemid 24256901)
4. W. Jessner, M. Gschwantler, P. Steindl-Munda, H. Hofer, T. Watkin-Riedel, and F. Wrba Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study Lancet 358 2001 1241 1242 (Pubitemid 33010853)
5. P. Ferenci, M.W. Fried, M.L. Shiffman, C.I. Smith, G. Marinos, and F.L. Goncales Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin J Hepatol 43 2005 425 433 (Pubitemid 41111423)
6. G.L. Davis, J.B. Wong, J.G. McHutchison, M.P. Manns, J. Harvey, and J. Albrecht Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C Hepatology 38 2003 645 652 (Pubitemid 37052151)
7. E. Durante-Mangoni, R. Zampino, G. Portella, L.E. Adinolfi, R. Utili, and G. Ruggiero Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment Clin Infect Dis 49 2009 498 506
8. D.M. Jensen, T.R. Morgan, P. Marcellin, P. Pockros, K.R. Reddy, and S.J. Hadziyannis Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy Hepatology 43 2006 954 960 (Pubitemid 43724620)
9. P. Ferenci, H. Laferl, T.M. Scherzer, M. Gschwantler, A. Maieron, and H. Brunner Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response Gastroenterology 135 2008 451 458
10. P. Marcellin, E.J. Heathcote, and A. Craxi Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen? J Hepatol 47 2007 580 587 (Pubitemid 47331763)
11. A. Mangia, N. Minerva, D. Bacca, R. Cozzolongo, G.L. Ricci, and V. Carretta Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial Hepatology 47 2008 43 50 (Pubitemid 351171040)
12. J.H. Hoofnagle, A.S. Wahed, R.S. Brown, C.D. Howell Jr., and S.H. Belle Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection J Infect Dis 199 2009 1112 1120
13. J.G. McHutchison, E.J. Lawitz, M.L. Shiffman, A.J. Muir, G.W. Galler, and J. McCone Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2002 580 593
14. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Jr. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
15. S.J. Hadziyannis, H. Sette Jr., T.R. Morgan, V. Bolan, M. Diago, and P. Marcellin Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
16. A.U. Neumann, S. Pianko, S. Zeuzem, E.M. Yoshida, Y. Benhamou, and M. Mishan Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C J Hepatol 51 1 2009 Jul 21 28
17. M. Martinot-Peignoux, S. Maylin, R. Moucari, M.P. Ripault, N. Boyer, and A.C. Cardoso Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin Antivir Ther 14 2009 501 511
18. J.L. Dienstag, and J.G. McHutchison American Gastroenterological Association medical position statement on the management of hepatitis C Gastroenterology 130 2006 225 230 (Pubitemid 43049855)
19. D.B. Strader, T. Wright, and D.L. Thomas Diagnosis, management, and treatment of hepatitis C Hepatology 39 2004 1147 1171 (Pubitemid 38428955)
20. M.G. Ghany, D.B. Strader, D.L. Thomas, and L.B. Seef Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
21. T. Berg, M. von Wagner, S. Nasser, C. Sarrazin, T. Heintges, and T. Gerlacht Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin Gastroenterology 130 2006 1086 1097
22. J.M. Sanchez-Tapias, M. Diago, P. Escartin, J. Enriquez, M. Romero-Gomez, and R. Barcena Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment Gastroenterology 131 2006 451 460 (Pubitemid 44142452)
23. P. Ferenci, H. Laferl, T.M. Scherzer, A. Maieron, H. Hofer, and R. Stauber Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response Gastroenterology 138 2010 503 512
24. B.L. Pearlman, C. Ehleben, and S. Saifee Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders Hepatology 46 2007 1688 1694
25. M. Buti, Y. Lurie, N.G. Zakharova, N.P. Biokhira, A. Horban, and G. Teuber Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response Hepatology 52 2010 1201 1207
26. G.L. Drusano, and S.L. Preston A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus J Infect Dis 189 2004 964 970 (Pubitemid 38373087)
27. P. Kwo, E.J. Lawitz, J. McCone, E.R. Schiff, J.M. Vierling, and D. Pound Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2010 705 716
28. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, and K.V. Shianna Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
29. A.F. Stättermayer, R. Stauber, H. Hofer, K. Rutter, S. Beinhardt, and T.M. Scherzer Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C Clin Gastroenterol Hepatol 9 4 2011 Apr 344 350
30. A.J. Thompson, A.J. Muir, M.S. Sulkowski, D. Ge, J. Fellay, and K.V. Shianna Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in hepatitis C virus-1 patients Gastroenterology 139 2010 120 129